From Sample to Insight: Technologies Driving the Future of Precision Oncology Assays
in precision oncology. As the field continues to advance, qPCR is maintaining its position as a frontline diagnostic tool—particularly in early cancer detection. Its unique combination of speed, affordability, sensitivity, and broad accessibility
makes it indispensable in both centralized labs and decentralized screening programs. Its continued dominance in early cancer diagnostics is driven by these strengths, alongside ongoing innovations that are expanding its clinical utility.
The Advantages of qPCR in Cancer Diagnostics
High Sensitivity for Low-Abundance Targets qPCR’s greatest strength lies in its ability to detect low-abundance targets with high analyt- ical sensitivity. This makes it especially effective for identifying trace levels of tumor DNA in early- stage disease, residual disease post-treatment, or in circulating biomarkers such as cell-free DNA (cfDNA). In FDA-approved companion diagnos- tics, qPCR’s high sensitivity enables the detection of clinically actionable mutations such as EGFR, BRAF, or KRAS ( Table 1 ).
qPCR is the most established and widely adopted molecular diagnostic technology for oncology, particularly in applications requiring rapid, high-sen- sitivity detection of known mutations. While technol- ogies like NGS offer broader insights, qPCR excels in delivering rapid, targeted results, especially for early detection, treatment selection and routine screening. Its proven role in companion diagnostics, minimal infrastructure needs, and automation compatibility make it ideal for both centralized labs and decentral- ized settings, securing its place as a frontline tool in precision oncology.
Table 1. Examples of real-world sensitivity levels from FDA-approved qPCR-based companion diagnostics.
22 | GENengnews.com
Powered by FlippingBook